Search

The use of nanoparticulate systems for pulmonary drug delivery offers a number of advantages including significantly improved delivery efficiency to deep lung and the improved bioavailability. The traditional nanoparticle manufacturing process such as ball/jet milling often yields large aggregates, which could detrimentally inhibit the effective delivery of drug particles to the lower respiratory tract. Here we report an alternative technique of spray-drying the microemulsions to produce nanoparticles (<100 nm) that can be dispersed homogenously in the propellant to form an extremely stable pressurized metered-dose inhaler (pMDI) formulations. Such nanoparticulate formulations provide an ideal tool for pulmonary drug delivery.

Therapeutic gene delivery systems offer the potential for the treatment of a range of inherited and acquired inherited diseases. In contrast with viral gene vectors, the nonviral gene vectors provide a safer alternative and additional advantages such as the improved delivery efficiency, low cost, and often unlimited capacity to package DNA. Here we describe the preparation of a nonviral gene delivery technique based on lipid-peptide-DNA (LPD) complexes. The size of LPD particles is in the nanometer range. The use of these nanoparticulate LPDs results in high efficiency transfections and a high level of gene expression in vitro. LPDs provide a convenient and efficient tool for gene delivery in gene therapy.

Therapeutic gene delivery systems offer the potential for the treatment of a range of inherited and acquired inherited diseases. In contrast with viral gene vectors, the nonviral gene vectors provide a safer alternative and additional advantage such as the improved delivery efficiency, low cost, and often unlimited capacity to package DNA. Here we describe preparation of nonviral gene delivery technique based on lipid:peptide:DNA (LPD) complexes. The size of LPD particles is in the nanometre range. The use of these nanoparticulate LPDs results in high efficiency transfections and a high level of gene expression in vitro. LPDs provide a convenient and efficient tool for gene therapy for the gene delivery.

The use of nanoparticulate systems for pulmonary drug delivery offers a number of advantages including the significantly improved delivery efficiency to the deep lung and the improved bioavailability. The traditional nanoparticle manufacturing process such as ball/jet milling may generate large aggregates, which could detrimentally inhibit the effective delivery of drug particles to the lower respiratory way. Here we report an alternative technique of spray-drying nanoemulsion to produce nanoparticles (<100 nm) that can be dispersed homogenously in the propellant to form an extremely stable pressurized metered dose inhaler formulation. Such nanoparticulate formulations dramatically improve the efficiency of drug delivery to the lungs, and therefore provide an ideal tool for pulmonary drug delivery.

Background: Multidrug resistance remains a major obstacle to successful cancer chemotherapy. Some chemical multidrug resistance inhibitors, such as ciclosporin and verapamil, have been reported to reverse resistance in tumor cells. However, the accompanying side effects have limited their clinical application. In this study, we have developed a novel drug delivery system, ie, a polyethyleneglycol-polycaprolactone (PEG-PCL) copolymer micelle encapsulating doxorubicin, in order to circumvent drug resistance in adriamycin-resistant K562 tumor cells., Methods: Doxorubicin-loaded diblock copolymer PEG-PCL micelles were developed, and the physicochemical properties of these micelles, and accumulation and cytotoxicity of doxorubicin in adriamycin-resistant K562 tumor cells were studied., Results: Doxorubicin-loaded micelles were prepared using a solvent evaporation method with a diameter of 36 nm and a zeta potential of +13.8 mV. The entrapment efficiency of doxorubicin was 48.6% ± 2.3%. The micelles showed sustained release, increased uptake, and cellular cytotoxicity, as well as decreased efflux of doxorubicin in adriamycin-resistant K562 tumor cells., Conclusion: This study suggests that PEG-PCL micelles have the potential to reverse multidrug resistance in tumor cells.